Netarsudil

證據等級: L5

預測適應症: 2 個

Netarsudil: From Open-Angle Glaucoma to Primary Hereditary Glaucoma

One-Sentence Summary

Netarsudil is a Rho-kinase (ROCK) inhibitor already used internationally to lower intraocular pressure in open-angle glaucoma and ocular hypertension (marketed abroad as Rhopressa®/Rocklatan®), though it is not currently registered in this market. The TxGNN model predicts potential efficacy in Primary Hereditary Glaucoma, a genetically-defined glaucoma subtype, but this specific link is currently supported by only 1 indirectly related clinical trial and no dedicated publications.

Quick Overview

Item	Content
Original Indication	Open-angle glaucoma / ocular hypertension (per published literature; no local license data available)
Predicted New Indication	Primary Hereditary Glaucoma
TxGNN Prediction Score	99.50%
Evidence Level	L4
Germany Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in the structured drug record. However, published literature in the evidence pack indicates netarsudil is a Rho-associated protein kinase (ROCK) inhibitor that also inhibits the norepinephrine transporter. It acts on the trabecular meshwork to increase aqueous humor outflow and reduces episcleral venous pressure, both of which lower intraocular pressure (IOP) — the core pathogenic driver in essentially all glaucoma subtypes.

Primary hereditary glaucoma is a genetically-determined subtype of glaucoma that shares the same fundamental pathophysiology as open-angle glaucoma: impaired aqueous outflow leading to elevated IOP. Since netarsudil's mechanism targets this shared outflow pathway rather than a disease-specific process, it is mechanistically plausible that the drug could be effective across glaucoma subtypes, including the hereditary form.

That said, the mechanistic plausibility is currently stronger than the direct clinical evidence. The only registered trial tagged to this specific indication (NCT06969586) targets corneal endothelial protection in patients with concurrent Fuchs endothelial corneal dystrophy — not IOP control in primary hereditary glaucoma — and was graded "C" (indirect relevance). By contrast, the broader "glaucoma" indication in this evidence pack is backed by an extensive body of evidence (30+ trials including multiple completed Phase 3 pivotal studies, and 20+ publications, several RCTs and a meta-analysis), which underpins netarsudil's existing FDA approval. This large body of general glaucoma evidence lends indirect mechanistic support to the hereditary-subtype prediction, but it does not substitute for subtype-specific confirmatory data.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06969586	N/A	Enrolling by Invitation	50	Evaluates whether topical ROCK inhibitors protect corneal endothelial cells after cataract surgery in patients with glaucoma and Fuchs endothelial corneal dystrophy. Designed to assess corneal endothelial cell loss, not IOP control specific to primary hereditary glaucoma; relevance graded C (indirect).

Literature Evidence

Currently no related literature available specific to primary hereditary glaucoma.

Safety Considerations

Structured safety data (key warnings, contraindications, drug interactions) has not yet been collected for netarsudil in this market's regulatory dataset. Please refer to the official package insert once available.

Note from literature: published studies on netarsudil (in its established glaucoma indication) report class-related ocular adverse effects, including conjunctival hyperemia, punctal stenosis/closure (PMID 36223296), and reticular epithelial corneal edema (PMID 41438161). These are literature-reported safety signals for the drug class/original indication, not confirmed prescribing information for the candidate hereditary-glaucoma indication.

Conclusion and Next Steps

Decision: Hold

Rationale: Direct evidence for primary hereditary glaucoma is limited to a single, indirectly related, early-stage trial (Grade C relevance) targeting a comorbid corneal condition rather than the hereditary glaucoma phenotype itself. While netarsudil's ROCK-inhibition mechanism and its extensive, well-established efficacy in general open-angle glaucoma provide plausible mechanistic support, no confirmatory studies exist for the hereditary subtype specifically, and the drug is not yet registered in this market.

To proceed, the following is needed:

Dedicated clinical trials assessing netarsudil's IOP-lowering efficacy specifically in primary hereditary glaucoma populations
Formal mechanism-of-action (MOA) documentation and local regulatory/package-insert safety data
Genetic-subtype-stratified outcome data confirming applicability of the ROCK-inhibition mechanism beyond general open-angle glaucoma
Local market registration data (licenses, approved indication text) to establish regulatory pathway feasibility
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.